Meeting
2022 ASCO Annual Meeting
Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer.
Authors
Bernardo Leon Rapoport
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
Bernardo Leon Rapoport , Helen C. Steel , Carol Benn , Simon Nayler , Teresa Smit , Liezl Heyman , Annette J. Theron , Nomsa Hlatswayo , Luyanda LI Kwofie , Pieter Meyer , Ronald Anderson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3044)
DOI
10.1200/JCO.2022.40.16_suppl.3044
Abstract #
3044
Poster Bd #
36
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Dysregulation of soluble immune checkpoint proteins in newly-diagnosed early breast cancer patients.
First Author: Bernardo Leon Rapoport
Poster
2023 ASCO Annual Meeting
Transforming growth factor-b1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma.
First Author: Bernardo Leon Rapoport
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Prognostic value of the expression of immunomodulatory targets in surgically resected lung adenocarcinoma.
First Author: Kazuya Takamochi
Poster
2017 ASCO Annual Meeting
Gene expression analysis of tumor biopsies from a trial of durvalumab to identify subsets of NSCLC with shared immune pathways.
First Author: Katie Streicher